南非医护人员接种Ad26.COV2.S疫苗的效果(Sisonke研究):单臂、开放标签、3B期实施研究结果
Sisonke研究为单臂、开放标签、3B期实施研究,2021年2月17日至5月17日在全国122个接种点纳入并接种477 102名18岁及以上医护人员,单剂5×10^10病毒颗粒Ad26.COV2.S疫苗。215 813名接种者与215 813名未接种者按COVID-19风险匹配。截至2021年7月17日,疫苗预防COVID-19相关死亡的有效性为83%(95%CI 75-89),预防需重症或重症监护住院的有效性为75%(69-82),预防COVID-19相关住院的有效性为67%(62-71)。研究期间beta(B.1.351)和delta(B.1.617.2)变异株先后占优势,疫苗有效性保持一致。
要点
- 单剂Ad26.COV2.S疫苗预防COVID-19相关死亡的有效性为83%(95%CI 75-89),预防需重症或重症监护住院的有效性为75%(69-82)。
- 预防COVID-19相关住院的有效性为67%(95%CI 62-71),在方案A和方案B两个医保数据库中结果一致。
- beta波期间预防住院有效性为62%(95%CI 42-76),delta波期间为67%(62-71)。
- beta波期间预防死亡有效性为86%(95%CI 57-100),delta波期间为82%(74-89)。
- 在年长医护人员及包括HIV感染在内的合并症人群中,疫苗有效性得以维持。
适用人群与场景
- 南非18岁及以上医护人员,2021年2月17日至5月17日在全国122个接种点接种单剂Ad26.COV2.S疫苗。
- 接种者与两个国家医保方案(方案A和方案B)中按COVID-19风险匹配的未接种普通人群比较。
诊断标准与关键阈值
- 主要结局为接种或匹配后28天及以上至数据截止时,与普通人群相比,疫苗预防重症COVID-19的有效性;重症COVID-19定义为COVID-19相关住院、需重症或重症监护的住院或死亡。
处置流程与药物剂量
- 参与者接受单剂5×10^10病毒颗粒的Ad26.COV2.S疫苗。
研究设计与关键结果
- 单臂、开放标签、3B期实施研究,纳入并接种477 102名医护人员,其中女性357 401名(74.9%)、男性119 701名(25.1%),中位年龄42.0岁(33.0-51.0)。
- 215 813名接种者与215 813名未接种者匹配;截至2021年7月17日数据截止,预防COVID-19相关死亡的有效性为83%(95%CI 75-89),预防需重症或重症监护住院的有效性为75%(69-82),预防COVID-19相关住院的有效性为67%(62-71)。
- 三个结局的疫苗有效性在方案A和方案B中一致。
- 疫苗有效性在年长医护人员及包括HIV感染在内的合并症人群中得以维持。
- 研究期间beta(B.1.351)和delta(B.1.617.2)变异株先后占优势,疫苗有效性保持一致:方案A加B预防COVID-19相关住院的有效性在beta波为62%(95%CI 42-76)、delta波为67%(62-71);预防COVID-19相关死亡的有效性在beta波为86%(57-100)、delta波为82%(74-89)。
证据类型、等级与局限
- 证据类型:单臂、开放标签、3B期实施研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 单剂Ad26.COV2.S疫苗在接种后对重症COVID-19和COVID-19相关死亡显示有效性,且对beta和delta变异株均显示有效性,为全球使用提供真实世界证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: We aimed to assess the effectiveness of a single dose of the Ad26.COV2.S vaccine (Johnson & Johnson) in health-care workers in South Africa during two waves of the South African COVID-19 epidemic.
METHODS: In the single-arm, open-label, phase 3B implementation Sisonke study, health-care workers aged 18 years and older were invited for vaccination at one of 122 vaccination sites nationally. Participants received a single dose of 5 × 1010 viral particles of the Ad26.COV2.S vaccine. Vaccinated participants were linked with their person-level data from one of two national medical insurance schemes (scheme A and scheme B) and matched for COVID-19 risk with an unvaccinated member of the general population. The primary outcome was vaccine effectiveness against severe COVID-19, defined as COVID-19-related admission to hospital, hospitalisation requiring critical or intensive care, or death, in health-care workers compared with the general population, ascertained 28 days or more after vaccination or matching, up to data cutoff. This study is registered with the South African National Clinical Trial Registry, DOH-27-022021-6844, ClinicalTrials.gov, NCT04838795, and the Pan African Clinical Trials Registry, PACTR202102855526180, and is closed to accrual.
FINDINGS: Between Feb 17 and May 17, 2021, 477 102 health-care workers were enrolled and vaccinated, of whom 357 401 (74·9%) were female and 119 701 (25·1%) were male, with a median age of 42·0 years (33·0-51·0). 215 813 vaccinated individuals were matched with 215 813 unvaccinated individuals. As of data cutoff (July 17, 2021), vaccine effectiveness derived from the total matched cohort was 83% (95% CI 75-89) to prevent COVID-19-related deaths, 75% (69-82) to prevent COVID-19-related hospital admissions requiring critical or intensive care, and 67% (62-71) to prevent COVID-19-related hospitalisations. The vaccine effectiveness for all three outcomes were consistent across scheme A and scheme B. The vaccine effectiveness was maintained in older health-care workers and those with comorbidities including HIV infection. During the course of the study, the beta (B.1.351) and then the delta (B.1.617.2) SARS-CoV-2 variants of concerns were dominant, and vaccine effectiveness remained consistent (for scheme A plus B vaccine effectiveness against COVID-19-related hospital admission during beta wave was 62% [95% CI 42-76] and during delta wave was 67% [62-71], and vaccine effectiveness against COVID-19-related death during beta wave was 86% [57-100] and during delta wave was 82% [74-89]).
INTERPRETATION: The single-dose Ad26.COV2.S vaccine shows effectiveness against severe COVID-19 disease and COVID-19-related death after vaccination, and against both beta and delta variants, providing real-world evidence for its use globally.
FUNDING: National Treasury of South Africa, the National Department of Health, Solidarity Response Fund NPC, The Michael & Susan Dell Foundation, The Elma Vaccines and Immunization Foundation, and the Bill & Melinda Gates Foundation.
参考来源
- Bekker LG, Garrett N, Goga A, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022. PMID: 35305740. doi:10.1016/S0140-6736(22)00007-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。